Eicosanoid release

Eicosanoid release refers to the complex biological process of mobilizing and converting polyunsaturated fatty acids, primarily arachidonic acid, into potent signaling molecules known as eicosanoids. This process is initiated by the enzyme Phospholipase A2 (PLA2), which cleaves arachidonic acid from cell membrane phospholipids in response to various stimuli (Dennis et al., 2011, Chemical Reviews). Once released, arachidonic acid is metabolized through several enzymatic pathways, most notably the cyclooxygenase (COX) pathway leading to prostaglandins and thromboxanes, and the lipoxygenase (LOX) pathway leading to leukotrienes (Funk, 2001, Science). These lipid mediators act as autocrine and paracrine signals that regulate critical physiological functions, including the inflammatory response, vascular tone, and platelet aggregation. In clinical medicine, the eicosanoid release pathway is a primary target for anti-inflammatory and analgesic therapy. Nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen work by inhibiting COX enzymes, thereby reducing the production of pro-inflammatory prostaglandins (Botting, 2006, Thrombosis Research). Corticosteroids act further upstream by inducing proteins like lipocortin that inhibit PLA2, effectively suppressing the entire cascade (Barnes, 2006, N Engl J Med). Because "Eicosanoid release" is a physiological process involving multiple enzymes and receptors rather than a single molecular target, it is classified as a biological pathway or pharmacological endpoint in drug discovery contexts.

Other names

Eicosanoid biosynthesisArachidonic acid cascadeEicosanoid productionLipid mediator release

Drugs typically modulate this process by inhibiting Phospholipase A2 (reducing precursor availability), inhibiting Cyclooxygenase (COX-1/COX-2) or Lipoxygenase (5-LOX) enzymes, or by acting as antagonists at downstream eicosanoid receptors.